Simon, Hans-UweHans-UweSimon0000-0002-9404-7736Karaulov, Alexander VAlexander VKaraulovBachmann, MartinMartinBachmann2024-09-022024-09-022020-06-16https://boris-portal.unibe.ch/handle/20.500.12422/36343A vaccine to protect against COVID-19 is urgently needed. Such a vaccine should efficiently induce high-affinity neutralizing antibodies which neutralize SARS-CoV-2, the cause of COVID-19. However, there is a concern regarding both vaccine-induced eosinophilic lung disease and eosinophil-associated Th2 immunopotentiation following infection after vaccination. Here, we review the anticipated characteristics of a COVID-19 vaccine to avoid vaccine-associated eosinophil immunopathology.enCOVID-19 Eosinophil Immunity Immunopathology SARS-CoV-2 Vaccination600 - Technology::610 - Medicine & healtharticle10.7892/boris.1449143254491110.1159/000509368